BioSpace News Archive

Ms. Flynn takes on the role previously held by Mr. Barry Littlejohns, who will be retiring.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of an equity award to a new employee with a grant date of January 13, 2020, as an equity inducement award outside of the company’s 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company.

RCP is HARMAN’s latest offering for healthcare which will further enable providers to digitize their services and processes to maintain pace with the market and patient demands.

John Madigan, senior vice president of public policy for the American Foundation for Suicide Prevention (AFSP), the nation’s largest suicide prevention organization, today released this statement:

This is the first contract with this health plan that provides coverage for the PLA.

Exactus, Inc. (OTCQB:EXDI) (the “Company”), a hemp farmer and manufacturer of hemp-derived phytocannabinoid products, today announced that it has appointed Daniel Alberttis to its Board of Directors.

HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO) is pleased to announce the results of its annual general meeting of shareholders held on January 15, 2020.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announces that it has entered into an agreement with the University Health Network (UHN) to perform a clinical experience program to enable it and three independent neurorehabilitation clinics in Canada to evaluate the Company’s Portable Neuromodulation Stimulator (PoNS™) device,

Scientist, business leader and innovator, Dr. Claudia Zylberberg, CEO of Akron Biotech in Boca Raton, will launch an updated version of her children’s book, You’re Full of Genes, during the Future of Medicine Day at the Phillip and Patricia Frost Museum of Science on January 20, 2020, from 11am-4pm ET.

TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, announced that the Company has initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting accelerated approval of umbralisib,